Overview

Location [1]
19p13.3
Protein [2]
Protein ENL
Synonyms [1]
LTG19, YEATS1, ENL

Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog; Drosophila); translocated to, 1 (MLLT1; also known as ENL) is a gene that encodes a protein that functions as a component of the super elongation complex (SEC). This complex facilitates the increase in the catalytic rate of RNA polymerase II. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as eye cancer, intestinal cancer, and skin cancer.

MLLT1 is altered in 0.12% of all cancers with lung adenocarcinoma, acute myeloid leukemia, bladder urothelial carcinoma, breast invasive ductal carcinoma, and cervical squamous cell carcinoma having the greatest prevalence of alterations [3].

MLLT1 GENIE Cases - Top Diseases

The most common alterations in MLLT1 are MLLT1 Fusion (0.02%), MLLT1 T129M (0.28%), MLLT1 A290T (0.39%), MLLT1 E416K (0.85%), and MLLT1 N430T (0.39%) [3].

MLLT1 GENIE Cases - Top Alterations

Significance of MLLT1 in Diseases

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Acute Lymphoblastic Leukemia +

Chronic Myeloid Leukemia +

Primary Myelofibrosis +

Hodgkin Lymphoma +

Myelofibrosis +

Non-Hodgkin Lymphoma +

Myelofibrosis Transformation In Essential Thrombocythemia +

Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase +

Chronic Lymphocytic Leukemia +

Multiple Myeloma +

Acute Biphenotypic Leukemia +

Chronic Myelomonocytic Leukemia +

Burkitt Lymphoma +

Myeloproliferative Neoplasm +

Secondary Myelofibrosis +

Acute Leukemia +

Anaplastic Large Cell Lymphoma +

Juvenile Myelomonocytic Leukemia +

Mantle Cell Lymphoma +

Follicular Lymphoma +

Marginal Zone Lymphoma +

Myelodysplastic/Myeloproliferative Neoplasm +

Lymphoma +

Small Lymphocytic Lymphoma +

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +

Diffuse Large B-Cell Lymphoma +

Double-Hit Lymphoma +

Prolymphocytic Leukemia +

Refractory Anemia With Excess Blasts +

B-Cell Non-Hodgkin Lymphoma +

Lymphoblastic Lymphoma +

Lymphoplasmacytic Lymphoma +

T-Cell Lymphoblastic Leukemia/Lymphoma +

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome +

Acute Undifferentiated Leukemia +

B-Cell Acute Lymphoblastic Leukemia +

Burkitt Leukemia +

Mature T-Cell And NK-Cell Lymphoma/Leukemia +

Mature T-Cell And NK-Cell Neoplasm +

Mediastinal Large B-Cell Lymphoma +

Mixed Phenotype Acute Leukemia +

Myelodysplastic Syndrome With Excess Blasts-2 +

Natural Killer Cell Lymphoblastic Leukemia/Lymphoma +

Plasma Cell Leukemia +

Secondary Acute Myeloid Leukemia +

T-Cell Acute Lymphoblastic Leukemia +

Therapy-Related Myelodysplastic Syndrome +

Malignant Solid Tumor +

Hematopoietic And Lymphoid Malignancy +

Acute Erythroid Leukemia +

Acute Leukemia Of Ambiguous Lineage +

Acute Megakaryoblastic Leukemia +

Acute Promyelocytic Leukemia +

Adult Acute Lymphoblastic Leukemia +

Adult T-Cell Leukemia/Lymphoma +

Aplastic Anemia +

Atypical Burkitt/Burkitt-Like Lymphoma +

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative +

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma +

B-Cell Prolymphocytic Leukemia +

Desmoplastic Small Round Cell Tumor +

Diffuse Large B-Cell Lymphoma Activated B-Cell Type +

Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation +

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified +

EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified +

EBV-Positive Mucocutaneous Ulcer +

Ewing Sarcoma +

Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma +

HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified +

High Grade B-Cell Lymphoma, Not Otherwise Specified +

Histiocytic And Dendritic Cell Neoplasm +

Indolent Non-Hodgkin Lymphoma +

Intravascular Large B-Cell Lymphoma +

Lymphomatoid Granulomatosis +

Mature B-Cell Lymphoma/Leukemia +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Myelodysplastic Syndrome With Excess Blasts-1 +

Myeloid Sarcoma +

Neuroblastoma +

Overt Primary Myelofibrosis +

Peripheral T-Cell Lymphoma +

Plasma Cell Neoplasm +

Plasmablastic Lymphoma +

Polycythemia Vera +

Primary Central Nervous System Lymphoma +

Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type +

Primary Effusion Lymphoma +

Refractory Anemia +

Rhabdomyosarcoma +

Secondary Myelodysplastic Syndrome +

Small Lymphocytic Leukemia +

T-Cell Non-Hodgkin Lymphoma +

T-Cell Prolymphocytic Leukemia +

T-Cell/Histiocyte-Rich Large B-Cell Lymphoma +

Therapy-Related Acute Myeloid Leukemia +

Therapy-Related Chronic Myelomonocytic Leukemia +

Triple-Hit Lymphoma +

Waldenstrom Macroglobulinemia +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.